Drug Interactions between atidarsagene autotemcel and Fluvirin

GENERALLY AVOID: The administration of inactivated, killed, or otherwise noninfectious vaccines has not been studied in patients receiving autologous hematopoietic stem cell (HSC)-based gene therapy (e.g., atidarsagene autotemcel, elivaldogene autotemcel). In general, patients who undergo myeloablative conditioning followed by autologous HSC-based gene therapy have altered immune competence, which may be associated with a diminished or suboptimal immunologic response to the vaccine. The myeloablative therapy performed prior to HSC transplant (HSCT) is believed to gradually remove immune memory acquired from previous vaccinations, with antibody titers to vaccine-preventable diseases decreasing 1 to 4 years after autologous HSCT if the recipient is not revaccinated.

MANAGEMENT: Vaccination is not recommended in the 6 weeks prior to the start of myeloablative conditioning and until there is demonstrated hematological recovery after the receipt of either atidarsagene autotemcel or elivaldogene autotemcel. Local vaccination guidelines specific to post-autologous HSCT and prescribing information for individual vaccines should be consulted for further guidance. For example, the Advisory Committee on Immunization Practices (ACIP) recommends initiating revaccination with many of these vaccines approximately 6 months after HSCT. The recommendations may differ based on age, immune status, presence of graft-versus-host disease, and specific vaccination being considered.

Switch to consumer interaction data